Skip to main content
. 2024 Apr 22;14(7):2719–2735. doi: 10.7150/thno.92350

Figure 5.

Figure 5

B. breve lw01 catabolizes L-tryptophan to release ILA. (A) PCA plot of β-diversity to measure the composition of colonic microbial metabolites in the B. breve group vs PBS group in CAC mice. (B) Heatmap of differential colonic metabolites detected by LC-MS/MS. (C) Correlation analysis between Bifidobacterium and ILA in CAC mice. (D) PCA plot of β-diversity to measure L-tryptophan and its downstream metabolites between B. breve lw01 and MRS supernatant. (E) Concentration for ILA production of B. breve lw01 metabolizing L-tryptophan in vitro. Data are represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. B. breve: Bifidobacterium breve; BCS: the culture supernatant of B. breve; CAC: colitis-associated colorectal cancer; ILA: indole-3-lactic acid; LC-MS/MS: liquid chromatography-tandem mass spectrometry; MRS: de Man, Rogosa and Sharpe medium; PCA: principal component analysis.